Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 1335 results for primary care

  1. Interim methods guide for developing service guidance 2014 (PMG8)

    Interim methods guide for developing service guidance 2014

  2. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  3. PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (MTG9)

    Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.

    Medical technologies guidance
    Last updated
    19 July 2022
    View recommendations

    Sections for MTG9

  4. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915

  5. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA768

  6. Multicomponent intervention: For people in long-term care, is a multicomponent non-pharmacological intervention more clinically and cost effective than usual care in preventing the development of delirium?

    people in long-term care, is a multicomponent non-pharmacological intervention more clinically and cost effective than usual...

    Research recommendation
    Published
    3 February 2023

  7. Transition in special groups: looked-after young people:- What is the most effective way of supporting care leavers in transition from children's to adults' health services?

    looked-after young people:- What is the most effective way of supporting care leavers in transition from children's to adults' health...

    Research recommendation
    Published
    21 March 2016

  8. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  9. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.

    Technology appraisal guidance
    Published
    26 May 2021
    View recommendations

    Sections for TA704

  10. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA405

  11. Managing glioma: early referral to palliative care for glioblastoma:- Does early referral to palliative care improve outcomes for people with glioblastomas in comparison with standard oncology care?

    Managing glioma: early referral to palliative care for glioblastoma:- Does early referral to palliative care improve...

    Research recommendation
    Published
    11 December 2018

  12. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA949

  13. Training in the use of the national quality standard and guidance on service user experience of care:- For people using adult mental health services, what is the effect of training community mental health teams (CMHTs) and inpatient ward staff in the use of the national quality standard and underpinning guidance on service user experience, when compared to no training, on service users' experience of care?

    the national quality standard and guidance on service user experience of care:- For people using adult mental health services, what is...

    Research recommendation
    Published
    9 June 2015

  14. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  15. Managing glioma: supportive care clinics for low-grade glioma:- Does a dedicated supportive care clinic in addition to standard care improve outcomes for people with low-grade gliomas?

    Managing glioma: supportive care clinics for low-grade glioma:- Does a dedicated supportive care clinic in addition to...

    Research recommendation
    Published
    11 December 2018